SGP
SpyGlass Pharma, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$610.16M
P/E Ratio
—
EPS
$-1.34
Beta
—
52W High
$32.44
52W Low
$17.60
50-Day MA
$22.21
200-Day MA
$24.21
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. (SGP) is a pioneering biopharmaceutical company focused on the development and commercialization of innovative therapies for critical health challenges. Its robust pipeline, underscored by state-of-the-art technologies, aims to address significant unmet medical needs and enhance patient care. Strategic partnerships bolster SGP's market position and foster growth, making the company a compelling investment prospect for institutional investors looking to capitalize on advancements within the dynamic biopharmaceutical landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-40.84M |
| Operating Margin | 0.00% |
| Return on Equity | -67.70% |
| Return on Assets | -37.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.48 |
| Price-to-Book | 2.41 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $33.43M |
| Float | $6.48M |
| % Insiders | 4.28% |
| % Institutions | 92.28% |
Historical Volatility
HV 10-Day
45.77%
HV 20-Day
46.10%
HV 30-Day
50.15%
HV 60-Day
70.18%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($45.00 target)
5
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026